Greenwich LifeSciences reports higher immune response rates in GLSI-100 Phase III FLAMINGO-01 open-label arm data at ASCO 2026

Greenwich LifeSciences, Inc.

Greenwich LifeSciences, Inc.

GLSI

0.00
  • Greenwich Lifesciences presented already-published ASCO 2026 open-label Phase III FLAMINGO-01 data for GLSI-100 in non-HLA-A02 breast cancer patients.
  • Preliminary findings showed more patients developed injection-site immune reactions with repeated dosing, supporting an on-treatment immune response over time.
  • The readout supports the strategy to use GLSI-100 beyond HLA-A02 patients, potentially expanding the addressable market and improving trial success odds.
  • The study remains ongoing, with final results subject to change as data collection and cleaning continue.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Greenwich Lifesciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606010815PRIMZONEFULLFEED9729399) on June 01, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.